Although the modulation of PD-L1/2+ DC populations differs between the circulation and tumor itself, our results suggest that in both locations, PSA− ENZR xenografts modulate DC PD-L1/2 expression more than CRPC or PSA+ ENZR cells, underscoring the potentially immunosuppressive features of non-AR driven resistant disease. This evidence concerns the gene CD274 and neoplasm.